Patent · US Active

HIV-1 clade a consensus sequences, antigens, and transgenes

US8735542B2 · kind B2 · utility

2Cited by
0References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 17, 2012
Grant dateMay 27, 2014
Priority date
Expiry dateFeb 17, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16322
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. Advantageously, the present invention relates to HIV-1 Clade A transgenes that are derived from such sequences, and that encode either HIV-1 Clade A Gag, Pol (RT and Int), and Nef (collectively “GRIN”), HIV-1 Clade A Gag, RT, and Nef (collectively “GRN”), or HIV-1 Clade A Env. The invention also relates to vectors containing such transgenes, including adenovirus vectors containing such transgenes. The invention also relates to immunogenic compositions comprising the HIV-1 Clade A antigens, nucleotide sequences, vectors, or transgenes of the invention, and to methods of generating an immune response against HIV in a subject by administering an effective amount of such immunogenic compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.